ArticleFrontiers in gastroenterology (Lausanne, Switzerland)2024
Enhancement of the stability and cytotoxicity of berberine by liposomal nanocarriers for gastric cancer treatment and its application in gummy candy.
Article in Frontiers in gastroenterology (Lausanne, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Parenteral Berberine vs Cisplatin- Loaded Lipid Nanoparticles - Development, Characterisation, Comparative Safety Profiling and Cytotoxicity in Cholangiocarcinoma Cell Models.Nanotechnology, science and applications · 2026Article
- In Vitro Evaluation of the Safety and Antineoplastic Effects in Gastrointestinal Tumors of Nanostructured Lipid Carriers Loaded with Berberine.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Berberine (BER), an isoquinoline alkaloid derived from the plant Berberis Vulgaris, is traditionally used to treat different types of disorders, such as cancer. However, its therapeutic application is limited due to poor solubility and low bioavailability. So, the main objective of the present work was to synthesize BER-loaded liposomes to enhance the solubility of BER. BER-loaded liposomes were synthesized using the thin-film hydration method. Methods: The prepared liposomes were characterized for size, surface charge, in vitro release, and cytotoxicity. Then, the synthesized nano-liposomes were used to enrich gummy candies, and physicochemical properties such as water activity (aw), instrumental texture, and sensory perception of the products were tested. Results and Discussion: The cell viability assay was performed on MKN-45P gastric cancer cell lines, and the results revealed that BER-loaded liposome had better cytotoxicity on MKN-45P cells than free BER. The IC50 values were calculated to be 66.72 µg/mL and 52.58 µg/mL for free BER and BER-loaded liposomes, respectively. Flow cytometric analysis demonstrated a significant anticancer effect of BER-loaded liposomes compared to free BER. These findings indicate that encapsulating BER preserves its antioxidant activity and enhances its bioavailability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.